We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Events

09 Apr 2024 - 12 Apr 2024
15 Apr 2024 - 17 Apr 2024
23 Apr 2024 - 26 Apr 2024

Genomic Test Aids in Determining Prostate Cancer Treatment Options

By LabMedica International staff writers
Posted on 06 Aug 2021
Print article
Real-world data support the clinical utility of the Decipher Prostate Biopsy Genomic Test for determining prostate cancer treatment options (Photo courtesy of Clinical Lab Products)
Real-world data support the clinical utility of the Decipher Prostate Biopsy Genomic Test for determining prostate cancer treatment options (Photo courtesy of Clinical Lab Products)
A clinical study has confirmed that a commercially available genomic test was useful for identifying which prostate cancer patients would benefit from more immediate and aggressive treatment.

Treatment of newly identified prostate cancer patients requires choosing between a watch-and-wait approach, known as active surveillance, or proceeding with surgery or radiation treatment.

Investigators at the University of Michigan (Ann Arbor, USA) assessed the clinical utility of the Veracyte (San Francisco, CA, USA) Decipher Biopsy test for identify patients who are at high risk of cancer progression and require a more aggressive treatment approach.

The Decipher Prostate Genomic Test was developed from a large cohort of metastatic and non-metastatic prostate cancer patients treated at the Mayo Clinic. This whole transcriptome test utilizes 22 coding and non-coding biomarkers that span seven cancer pathways to provide a more accurate, independent prediction of risk.

In the current study, 855 patients underwent Decipher Biopsy testing between February 2015 and October 2019. Cumulative incidence curves for time to treatment (TTT) and time to failure (TTF) were constructed using Kaplan–Meier estimates. Multivariable Cox proportional hazard models were used to evaluate the independent association of high-risk Decipher scores with the conversion from active surveillance (AS) to radical therapy and treatment failure.

Results revealed that of the 855 men, 264 proceeded to AS (31%), and 454 (53%) received radical therapy. In men electing AS, after adjusting for age, PSA (prostate specific antigen), prostate volume, body mass index, and percent positive cores, a high-risk Decipher score was independently associated with shorter TTT. Similarly, in patients that underwent radical therapy, a high-risk Decipher score was independently associated with TTF. Furthermore, following removal of the prostate gland, high Decipher scores were associated with shorter time until recurrence of elevated PSA levels or when patients were put on anti-androgen therapy.

"Men with a high Decipher score who were placed on active surveillance had a shorter time before active treatment was needed," said first author Dr. Randy Vince, Jr., an oncology fellow at the University of Michigan. "We have long needed better tools to reduce the uncertainty of these initial treatment decisions."

Results of the Decipher clinical study were published in the July 20, 2021, online edition of the journal Prostate Cancer and Prostatic Diseases.

Related Links:

University of Michigan
Veracyte


Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Specimen Collection & Transport
POCT Fluorescent Immunoassay Analyzer
FIA Go
Gold Member
Xylazine Immunoassay Test
Xylazine ELISA

Print article

Channels

Clinical Chemistry

view channel
Image: Reaching speeds up to 6,000 RPM, this centrifuge forms the basis for a new type of inexpensive, POC biomedical test (Photo courtesy of Duke University)

POC Biomedical Test Spins Water Droplet Using Sound Waves for Cancer Detection

Exosomes, tiny cellular bioparticles carrying a specific set of proteins, lipids, and genetic materials, play a crucial role in cell communication and hold promise for non-invasive diagnostics.... Read more

Hematology

view channel
Image: The low-cost portable device rapidly identifies chemotherapy patients at risk of sepsis (Photo courtesy of 52North Health)

POC Finger-Prick Blood Test Determines Risk of Neutropenic Sepsis in Patients Undergoing Chemotherapy

Neutropenia, a decrease in neutrophils (a type of white blood cell crucial for fighting infections), is a frequent side effect of certain cancer treatments. This condition elevates the risk of infections,... Read more

Pathology

view channel
Image: The OvaCis Rapid Test discriminates benign from malignant epithelial ovarian cysts (Photo courtesy of INEX)

Intra-Operative POC Device Distinguishes Between Benign and Malignant Ovarian Cysts within 15 Minutes

Ovarian cysts represent a significant health issue for women globally, with up to 10% experiencing this condition at some point in their lives. These cysts form when fluid collects within a thin membrane... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.